Recent News

• 11.05.2026 - HUTCHMED Announces Sovleplenib Granted US FDA Orphan Drug Designation for Autoimmune Hemolytic Anemia
• 11.02.2026 - HUTCHMED Announces Regulatory Filings Accepted for Review for ORPATHYS® plus TAGRISSO® in MET-Driven EGFR-Mutated Lung Cancer in Europe and Japan
• 10.29.2026 - HUTCHMED Announces Sovleplenib Granted US FDA Orphan Drug Designation for Primary Immune Thrombocytopenia
• 10.27.2026 - Save the Date: HUTCHMED to Host Expert Insights Event on Recent Savolitinib Clinical Data in Non-Small Cell Lung Cancer
• 10.26.2026 - HUTCHMED Highlights SANOVO Phase III Data for ORPATHYS® plus TAGRISSO® in First-Line EGFR-Mutated Lung Cancer Presented at ESMO Congress 2026
• 10.26.2026 - HUTCHMED Highlights SAFFRON Global Phase III Data Presented at ESMO Congress 2026 and Simultaneously Published in The New England Journal of Medicine
• 10.21.2026 - HUTCHMED Announces Closing of KRAS-EGFR-Antibody Conjugate Therapy License to GSK Outside China
• 09.29.2026 - HUTCHMED Announces Submission of US NDA for ORPATHYS® plus TAGRISSO® in MET-Driven EGFR-Mutated Lung Cancer
• 09.28.2026 - HUTCHMED Initiates Global Trial of KRAS-EGFR-Antibody Conjugate Therapy HMPL-A830 in Patients with Solid Tumors
• 09.24.2026 - HUTCHMED Highlights Clinical Data to be Presented at the ESMO Congress 2026

Recent Filings

• 11.05.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 11.05.2026 - EX-99.1 EX-99.1
• 11.02.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 11.02.2026 - EX-99.1 EX-99.1
• 10.29.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 10.29.2026 - EX-99.1 EX-99.1
• 10.27.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 10.27.2026 - EX-99.1 EX-99.1
• 10.26.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 10.26.2026 - EX-99.1 EX-99.1